Wuhan Healthgen Biotechnology Corp in Wuhan East Lake High-tech Development Zone (Optics Valley of China, or OVC) has achieved mass production of the world's first plant-derived recombinant human serum albumin (HSA) injectable preparations, known as OsrHSA Precise, with an annual production capacity of 1 million bottles.

Yang Daichang, chairman of Healthgen Biotechnology, announced that the first batch, having passed quality inspections, is set to be distributed via cold chain logistics to distributors and medical institutions across 31 provinces and cities in China. 

The plant-derived HSA injectable preparations are produced at Healthgen Biotechnology's smart factory. [Photo/WeChat account of Optics Valley of China]

Healthgen Biotechnology is a pioneer in the insertion of the human serum albumin gene into rice, allowing every kilogram of rice to produce 20 to 30 grams of albumin. This breakthrough technology holds international patents in China, the United States, Japan, and Europe.

This innovation has reduced China's dependence on imported human serum albumin, crucial for treating severe conditions like burns and liver failure, which previously could only be extracted from human plasma.

The first phase of Healthgen Biotechnology's industrial base for plant-derived recombinant HSA has been completed, with equipment installation and testing now underway. The facility is expected to be operational by the first half of next year, increasing OsrHSA Precise's annual production capacity to 13 million bottles.

The product has received approval for Phase III clinical trials in the United States. Upon successful completion, it will be eligible for all existing clinical indications of approved human serum albumin, benefiting patients with clinical needs worldwide.